“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can...
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...